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Abstract
Introduction:  Vascular  endothelial  growth  factor  is  thought  to  be  an  important  angiogenic  factor
involved in  tumor  growth,  progression,  and  metastasis.
Objective:  The  present  study  evaluated  the  relation  between  tissue  expression,  serum  and
salivary levels  of  vascular  endothelial  growth  factor  in  head  and  neck  squamous  cell  carcinomas,
and their  correlation  with  clinicopathologic  features.
Methods:  Samples  were  collected  from  30  patients  with  head  and  neck  squamous  cell  carcino-
mas and  24  healthy  volunteers.  Immunohistochemical  analysis  was  used  for  tissue  expression
and enzyme-linked  immunosorbent  assay  was  employed  to  measure  serum  and  salivary  levels.
Results: No  vascular  endothelial  growth  factor  staining  was  observed  in  normal  tissues,  whereas
vascular endothelial  growth  factor  expression  was  seen  in  6  patients  (20%).  Mean  serum  level  of
VEGF was  83.7  ±  104.47  in  patients  and  50.04  ±  32.94  in  controls.  Mean  salivary  level  of  vascular
endothelial  growth  factor  was  174.41  ±  115.07  in  patients  and  149.58  ±  101.88  in  controls.  No
signiﬁcant  difference  was  found  by  Mann--Whitney  test  between  controls  and  patients  (p  =  0.411,
p =  0.944,  respectively).  No  correlation  was  found  between  vascular  endothelial  growth  factor
tissue expression  and  its  serum  and  salivary  level. Please cite this article as: Andisheh-Tadbir A, Hamzavi M, Rezvani G, Ashraf MJ, Fattahi MJ, Khademi B, et al. Tissue expression, serum
and salivary levels of vascular endothelial growth factor in patients with HNSCC. Braz J Otorhinolaryngol. 2014;80:503--7.
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Conclusion:  Overexpression  of  vascular  endothelial  growth  factor  was  found  in  head  and  neck
squamous cell  carcinoma  patients,  suggesting  its  role  in  the  pathogenesis  of  head  and  neck
squamous  cell  carcinoma,  but  no  relation  was  found  between  tissue  expression,  serum  levels,
and salivary  levels  of  this  marker.
©  2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Expressão  tecidual,  soro  e  níveis  salivares  de  VEGF  em  pacientes  com  carcinoma  de
células  escamosas  de  cabec¸a e  pescoc¸o
Resumo
Introduc¸ão: Acredita-se  que  o  fator  de  crescimento  vascular  endotelial  (FCEV)  seja  um  impor-
tante fator  angiogênico  envolvido  no  crescimento,  na  progressão  e  na  metástase  tumoral.
Objetivo:  O  presente  estudo  avalia  a  relac¸ão  entre  a  expressão  tecidual  e  os  níveis  séricos  e
salivares do  FCEV  em  carcinomas  de  células  escamosas  da  cabec¸a  e  pescoc¸o  (CCECPs)  e  sua
correlac¸ão com  aspectos  clinicopatológicos.
Método:  Foram  coletadas  amostras  de  30  pacientes  com  CCECP  e  de  24  voluntários  saudáveis.
Utilizamos  análise  imuno-histoquímica  para  a  expressão  tecidual  e  ELISA  para  determinac¸ão  dos
níveis séricos  e  salivares.
Resultados:  Não  foi  observada  colorac¸ão  para  FCEV  nos  tecidos  normais,  enquanto  que  foi
observada  expressão  de  FCEV  em  seis  pacientes  (20%).  O  nível  sérico  médio  de  FCEV  foi
83,7 ±  104,47  em  pacientes  e  50,04  ±  32,94  em  controles.  O  nível  salivar  médio  de  FCEV  foi  de
174,41 ±  115,07  em  pacientes  e  149,58  ±  101,88  em  controles.  Não  foi  observada  diferenc¸a sig-
niﬁcativa  pelo  teste  de  Mann-Whitney  entre  controles  e  pacientes  (respectivamente,  p  =  0,411,
p =  0,944).  Não  foi  observada  relac¸ão  entre  a  expressão  tecidual  de  FCEV  e  seus  níveis  séricos
e salivares.
Conclusão:  A  expressão  elevada  de  FCEV  foi  observada  em  pacientes  com  CCECP,  e  isso  sugere
seu papel  na  patogênese  de  CCECP,  mas  não  foi  observada  relac¸ão  entre  a  expressão  tecidual
e os  níveis  séricos  e  salivares  desse  marcador.
© 2014  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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infection,  autoimmune  disease,  inﬂammatory  disease,  orntroduction
ngiogenesis  is  an  important  phenomenon  in  the  devel-
pment  of  tumors  and  metastasis,  which  is  created  by
ecretion  of  several  growth  factors  by  means  of  tumor
ells  and  tumor  surroundings.  Although  tumor  development
s  a  multiple  phase  process,  angiogenesis  is  necessary  for
umor  growth  and  metastasis.1,2 Vascular  endothelial  growth
actor  (VEGF)  is  known  to  be  a  fundamental  regulator  of
ngiogenesis  that  accelerates  cellular  proliferation,  vascu-
ar  permeability,  and  endothelial  cell  migration,  as  well  as
unctioning  as  an  apoptosis  inhibitor.3 VEGF  is  a  heparin
inding  glycoprotein  and  its  gene  is  located  on  chromosome
.1 This  protein  is  the  most  important  of  VEGF  family  and  has
 role  in  vascular  permeability.4 Inhibition  of  VEGF  activity
eads  to  diminished  growth  and  decreased  tumor  progres-
ion,  which  suggests  that  it  has  an  important  role  in  initiation
f  tumor  angiogenesis.5 Furthermore,  it  has  been  deter-
ined  that  hypoxia  can  increase  VEGF  expression,  and  that
EGF  overexpression  leads  to  angiogenesis  in  the  hypoxic
rea  of  tumors.6
VEGF  is  expressed  in  several  malignant  tumors,  which
ndicates  its  important  role  in  the  process  of  angiogenesis.
p
t
cver-expression  of  VEGF  has  been  found  in  solid  tumors,
uch  as  those  of  the  colon,  kidney,  breast,  brain,  pancreas,
ladder,  ovary,  stomach,  lung,  and  oral  cavity.7
Regarding  the  role  of  VEGF  in  the  angiogenic  process,  the
im  of  this  study  was  to  investigate  the  expression,  serum
nd  salivary  levels  of  this  marker  in  patients  with  head  and
eck  squamous  cell  carcinoma  (HNSCC).
ethods
n  this  cross-sectional  study,  30  patients  with  HNSCC  (21
ales  and  nine  females),  who  were  referred  to  Khalili  and
hamran  Hospitals  of  Shiraz  University  of  Medical  Sciences,
ere  examined.  The  control  group  consisted  of  24  healthy
ndividuals  (16  male  and  eight  females)  who  were  matched
ith  the  patients  group  in  terms  of  age  and  sex.
Those  suffering  from  any  systematic  disease,  activeeriodontal  problems  were  excluded  from  the  study.  As  for
he  patients  group,  those  who  had  a  history  of  radiotherapy,
hemotherapy,  or  other  cancers  were  excluded.
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Table  1  Clinicopathological  proﬁle  of  30  head  and  neck
squamous  cell  carcinoma  patients.
Clinicopathological  proﬁle  n  (%)
Gender
Male  21  (70%)
Female 9  (30%)
Tumor size
T1  12  (40%)
T2 18  (60%)
Regional  lymph  node  involvement
N0  27  (90%)
N1 3  (10%)
Distant metastasis
M0  30  (100%)
TNM stage
I  11  (36.7%)
II 16  (53.3%)
III 3  (10%)
Histological  grade
I (well-diff.) 8  (26.7%)
II (moderately-diff.) 18  (60%)
III (poorly-diff.) 4  (13.3%)
Location
Larynx 22  (73.3%)
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H&E  slides  were  examined  in  patients  with  HNSCC  and
those  with  sufﬁcient  tissue  were  selected  for  immunohis-
tochemical  (IHC)  studies.  Clinical  information  of  patients,
including  age,  sex,  tumor  location,  tumor  size,  metastasis
stage  and  grade,  as  well  as  tobacco  consumption  habits,
were  collected  from  the  patients’  records.  The  Ethics  Com-
mittee  of  Shiraz  University  of  Medical  Sciences  approved  the
study  and  all  patients  signed  an  informed  consent.
To  prepare  serum,  5  cm3 of  blood  was  drawn  from  the
patients’  veins,  who  were  NPO  for  12  h,  in  the  morn-
ing  before  surgery.  The  blood  samples  were  immediately
centrifuged  at  3000  rpm  for  10  min.  The  serum  was  then
separated  and  stored  at  −80 ◦C  until  analysis.8
In  order  to  collect  saliva,  unstimulated  whole  saliva  sam-
ples  were  collected  from  the  patients,  who  were  NPO  for
12  h,  in  the  morning  before  surgery.
The  patients  were  asked  to  refrain  from  eating,  drink-
ing,  and  smoking  for  30  min.  Then,  the  patients’  lips  were
cleaned  and  each  patient  rinsed  his/her  mouth  with  water.
Approximately  5--10  mL  saliva  was  collected  from  every
patient.  After  centrifugation  of  the  samples  (2600  ×  g,
15  min,  40 ◦C),  they  were  then  stored  at  −80 ◦C  until  use.9
Serum  and  saliva  analysis
Concentration  of  VEGF  was  measured  using  enzyme-linked
immunosorbent  assay  (ELISA)  (Bender  Med.  Systems  GmbH
-- Germany),  according  to  the  manufacturer’s  instructions.
Immunohistochemical  staining
IHC  staining  was  performed  by  using  the  EnVision® Labeled
Peroxidase  System  (DAKO,  Carpentaria,  CA,  USA).  All  sam-
ples  were  ﬁxed  in  10%  buffered  formalin  and  were  embedded
in  parafﬁn.  Sections  with  4  m  thickness  were  prepared,
deparafﬁnized  in  xylene,  rehydrated  in  graded  alcohol,  and
washed  with  distilled  water.  Antigen  retrieval  was  per-
formed  by  using  DAKO  cytomation  target  retrieval  solution
with  pH  =  9,  for  20  min.  Internal  peroxidase  activity  was
inhibited  by  3%  H2O2.  Tissue  sections  were  then  incubated
for  30  min  with  the  anti-VEGF  antibody  (mouse  anti-human;
DAKO  Corporation  --  Denmark)  at  a  1:25  dilution.  Normal
samples  were  stained  with  the  same  amount  of  antibody
used  for  staining  tumor  tissues.  Omission  of  the  primary
antibody  was  employed  as  negative  control,  while  pyogenic
granuloma  was  used  as  positive  control.  Brown  cytoplasmic
staining  for  VEGF  was  considered  as  positive.
The  stained  slides  were  initially  scanned  at  low  mag-
niﬁcation.  For  the  slides  showing  heterogeneous  staining,
the  regions  with  higher  staining  were  studied.  Five  ﬁelds
were  randomly  chosen,  500  cells  were  counted,  and  the  per-
centage  of  staining  was  calculated.  The  extent  of  staining
was  classiﬁed  as:  0  if  0--10%  of  tumor  cells  were  stained,
1  if  11--25%  of  tumor  cells  were  stained,  2  if  26--50%  were
stained,  and  3  if  more  than  50%  were  stained.Statistical  analysis
After  entering  the  data  into  the  statistical  software  (SPSS
18.0),  the  normality  of  the  data  was  ﬁrst  examined  using  the
v
1
f
(Oral cavity  8  (26.7%)
olmogorov--Smirnov  test.  As  the  variables  under  study  were
ot  normally  distributed,  Mann--Whitney,  Kruskal--Wallis,
nd  chi-squared  tests  were  used  in  order  to  compare  the  two
roups.  Differences  were  considered  signiﬁcant  at  p  <  0.05.
esults
escription  of  variables
he  present  study  was  performed  on  30  patients  with
NSCC  (21  males  and  nine  females)  with  a  mean  age  of
6.76  ±  12.46  years.  Clinicopathologic  characteristics  of  the
atients  are  shown  in  Table  1.
No  VEGF  staining  was  observed  in  normal  tissues,  whereas
EGF  expression  was  observed  in  six  patients  (20%);  four  had
cores  of  1  and  two  had  scores  of  2.  VEGF  expression  was  not
een  around  keratin  pearls  (Figs.  1  and  2).
The  results  indicated  that  the  tissue  expression  of  VEGF
etween  cases  and  controls  showed  a  signiﬁcant  difference
p:  0.023),  such  that  it  was  higher  in  the  HNSCC  group  than
he  controls.  There  was  no  apparent  correlation  in  VEGF
xpression  with  the  clinicopathological  features,  such  as
tage,  tumor  size,  nodal  status,  and  histological  grade.
The  mean  serum  level  of  VEGF  was  83.7  ±  104.47  in
atients  and  50.04  ±  32.94  in  controls.  The  mean  sali-
ary  level  of  VEGF  was  174.41  ±  115.07  in  patients  and
49.58  ±  101.88  in  controls.  No  signiﬁcant  difference  was
ound  by  Mann--Whitney  test  between  controls  and  patients
p  =  0.411,  p  =  0.944,  respectively).
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1 mm
Figure  1  Cytoplasmic  staining  of  vascular  endothelial  growth
factor in  squamous  cell  carcinoma  (200×).
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eigure  2  Vascular  endothelial  growth  factor  expression  was
egative  around  keratin  pearls  (100×).
No  signiﬁcant  correlation  was  found  by  Mann--Whitney
est  between  VEGF  tissue  expression  and  its  serum  and
alivary  levels  (p  =  0.517,  p  =  0.716,  respectively).  The  rela-
ionships  between  serum  and  salivary  levels  of  VEGF  and
ther  variables  such  as  age,  sex,  M,  N,  T,  grade,  and  stage
ere  separately  examined,  and  no  signiﬁcant  relationship
as  found  between  serum  or  salivary  levels  and  the  men-
ioned  variables.
iscussion
EGF  has  been  recognized  as  an  effective  factor  for  induc-
ion  of  angiogenesis  and  is  a  potent  mitogen  for  endothelial
ells.10 In  the  present  study,  the  expression  of  VEGF  was  seen
n  20%  of  tumor  samples,  while  none  of  the  tissues  of  control
roup  were  positive,  and  there  was  signiﬁcant  difference
egarding  the  expression  of  VEGF.  The  increased  expression
f  VEGF  in  the  present  study  is  in  accordance  with  the  other
tudies  which  were  performed  on  oral  SCC  and  HNSCC.10--12
owever,  the  rate  of  expression  of  VEGF  in  the  present  study
as  low  compared  to  other  studies,  which  may  be  due  to
ew  patients  in  this  study  when  compared  to  other  stud-
es.  The  relationship  between  the  expression  of  VEGF  and
he  parameters  such  as  tumor  differentiation,  lymph  nodes
etastasis,  and  depth  of  invasion  has  been  investigated
n  different  studies.13 The  results  regarding  the  investiga-
ion  of  relationship  between  the  expression  of  VEGF  and
t
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he  above-mentioned  factors  in  HNSCC  were  different.  Tse
t  al.14 found  that  there  was  no  relationship  between  VEGF
xpression  and  histopathologic  grade  and  location  of  tumor,
ut  that  increased  VEGF  expression  resulted  in  decreased
urvival  rate.  Kyzas  et  al.15 found  no  relationship  between
he  expression  of  VEGF,  grade,  and  stage  of  head  and  neck
arcinoma.  They  declared  that  the  expression  of  VEGF  in
enign  lesions  was  greater  than  in  carcinomas  and  dyspla-
ia;  in  addition,  they  found  that  the  expression  of  VEGF  has
 key  role  in  adjusting  the  normal  physiologic  condition  of
he  mucosa.  In  this  study,  there  was  no  relationship  between
he  VEGF  expression  and  clinicopathologic  factors.  Contro-
ersies  and  different  ﬁndings  may  be  due  to  few  samples,
ifferent  grading  of  VEGF  expression,  variety  of  tumors  with
egard  to  the  primary  location,  and  the  different  stages  of
he  patients  between  the  present  study  and  other  studies.  In
he  present  study,  most  of  the  patients  were  in  stages  I  and
I.  In  this  study,  serum  level  of  VEGF  in  patient  group  was
lightly  higher  than  control  group;  nonetheless,  this  differ-
nce  was  not  signiﬁcant  (p  >  0.05).  In  contrast  in  the  other
tudies,  increased  serum  level  of  VEGF  was  observed  in  the
atient  group.7,16 A  strong  relation  was  seen  between  VEGF
erum  level  and  HNSCC  in  patients  with  advanced  stages.17
n  fact,  in  the  other  studies,  the  majority  of  patients  were  in
dvanced  stages,  different  from  the  present  study  in  which
he  majority  of  patients  were  in  stages  I  and  II  without  dis-
ant  metastasis.  Thus,  it  is  more  accurate  to  compare  this
tudy  with  similar  studies  such  as  that  of  Wu  and  Meyer.18,19
n  their  study,  most  of  the  patients  were  in  stages  I and  II,
nd  most  of  the  lesions  were  located  in  the  larynx.  No  sig-
iﬁcant  elevation  in  VEGF  level  was  observed  in  their  study.
n  the  current  study,  there  was  no  relation  between  the
EGF  serum  level  and  clinicopathologic  factors,  while  in  the
tudy  conducted  by  Shang  et  al.,8 elevated  level  of  VEGF
as  present  in  patients  with  lymph  node  metastasis.  How-
ver,  in  a  study  by  Meyer  et  al.,18 which  is  quite  similar  to
he  present  study  regarding  the  selection  of  samples,  the
tage,  and  location  (samples  of  larynx  were  investigated),
here  was  no  relationship  between  the  circulating  VEGF  level
nd  clinicopathologic  factors.  Saliva  is  one  of  the  body  ﬂuids
hich  is  easily  accessible  and  its  preparation  is  noninvasive.
t  is  known  as  the  ‘‘mirror  of  body’’,  and  its  application  was
nvestigated  in  the  diagnosis  of  systemic  diseases  and  tumor
arkers.20 Saliva  is  identiﬁed  as  a  source  of  VEGF.  It  has
een  demonstrated  that  physiologic  and  pathologic  angio-
enesis  in  oral  mucosa  and  salivary  tissues  is  regulated  by
alivary  VEGF.21 The  presence  of  VEGF  in  the  saliva  of  normal
atients  suggests  the  important  role  of  VEGF  in  maintain-
ng  the  homeostasis  of  mucous  membranes.22 In  the  present
tudy,  the  VEGF  salivary  level  in  patients  with  HNSCC  was
igher  than  that  of  the  control  group,  but  there  was  no  sta-
istically  signiﬁcant  difference.  In  a  study  by  Upile  et  al.,23
he  salivary  level  of  VEGF165  was  examined,  and  the  results
emonstrated  that  the  VEGF  salivary  and  serum  levels  in
atients  were  signiﬁcantly  higher  than  those  of  the  control
roup.  In  their  study,  the  level  of  VEGF165  was  investigated
y  immunoassay,  while  in  the  current  study,  the  salivary  lev-
ls  of  various  isoforms  of  VEGF  was  investigated  by  ELISA;
his  difference  may  result  from  the  diversity  in  the  mea-
urement  of  isoforms.  In  the  present  study,  there  was  no
elationship  between  the  salivary  level  of  VEGF  and  clin-
copathologic  factors.  In  the  study  by  Upile  et  al.,23 the
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relationship  between  the  VEGF  salivary  level  and  clinico-
pathologic  factors  was  not  investigated.  In  reviewing  the
article,  the  present  authors  did  not  ﬁnd  any  studies  which
investigated  the  relationship  between  the  salivary  level  of
VEGF  and  clinicopathologic  factors.
Conclusion
In  the  present  study,  overexpression  of  VEGF  was  found  in
HNSCC  patients,  which  suggests  its  role  in  the  pathogenesis
of  HNSCC,  but  no  relation  was  found  between  the  tissue
expression,  serum  level,  and  salivary  level  of  this  marker.
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